Qiagen (QGEN) announced it has entered into a collaboration with Eli Lilly (LLY) to support the development of a QIAstat-Dx in-vitro diagnostic, or IVD, to detect APOE genotypes which can play a role in the diagnosis of Alzheimer’s disease. This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping. The panel will be integrated with Qiagen’s multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for a clinical application of the system in neurodegenerative diseases and adding to two more collaborations for diagnostics development programs with other companies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease
- QIAGEN N.V. announces conversion price of new net share settled convertible bonds
- Qiagen Launches $450 Million Convertible Bond Offering
- QIAGEN N.V. announces successful placement of new net share settled convertible bonds
- QIAGEN N.V. launches non-US offering of net share settled convertible bonds